Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK0001886575Filer CCCXXXXXXXIs this a LIVE or TEST Filing?IVE TESTSubmission Contact InformationIVE

Name Phone E-Mail Address

144: Issuer Information

Name of Issuer	Crinetics Pharmaceuticals, Inc.
SEC File Number	001-38583
Address of Issuer	10222 BARNES CANYON ROAD, BLDG. #2 SAN DIEGO CALIFORNIA 92121
Phone	858-450-6464
Name of Person for Whose Account the Securities are To Be Sold	Betz Stephen F.
	•••••••••••••••••••••••••••••••••••••••

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Relationship to Issuer Officer Co-Founder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Socuritioe
Common	Ameriprise Financial 2865 Ameriprise Financial Center Minneapolis MN 55474	3000	112950.00	66799257	01/10/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the	Date you	Nature of	Name of	Is	Date	Amount of	Date of	Nature of
Class	Acquired	Acquisition	Person from	this	Donor	Securities	Payment	Payment *

	Transaction	Whom Acquired	a Acquire Gift?	d Acquired	
Common	03/16/2015 Purchased on open market	N/A		3000	03/16/2015 Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Stephen Betz 1220 Highland Drive Del Mar CA 92014	Common	12/26/2023	3000	107679.60
Stephen Betz 1220 Highland Drive Del Mar CA 92014	Common	12/11/2023	3000	98598.90
Stephen Betz 1220 Highland Drive Del Mar CA 92014	Common	11/27/2023	3000	95206.20

144: Remarks and Signature

Remarks	Sale made as part of a 10B5-1 plan
Date of Notice	01/10/2024
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/25/2023
ATTENTION:	

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Alexander Meginnes as a duly authorized representative of Ameriprise Financial Services Inc, as attorney-in-fact for Stephen Betz

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)